Submit Manuscripts
Author Information
Subscribe/Renew
Email Alerts
Feedback
RSS Feed

About the Journal
Editorial Board & Staff

Interventions Homepage Imaging Homepage Interventions Homepage Imaging Homepage

ACC.org
Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions


ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction

ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease
cardiology careers collections past issues search home
     

J Am Coll Cardiol, 2005; 45:308-311, doi:10.1016/j.jacc.2004.10.062
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (70)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goy, J.-J.
Right arrow Articles by Seydoux, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goy, J.-J.
Right arrow Articles by Seydoux, C.

EXPRESS PUBLICATIONS

A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology

The TAXi trial

Jean-Jacques Goy, MD, FESC*, Jean-Christophe Stauffer, MD, FACC, Manon Siegenthaler, Alain Benoît and Charles Seydoux, MD

Service of Cardiology, Clinique Cecil, Lausanne, Switzerland

Manuscript received September 23, 2004; revised manuscript received October 10, 2004, accepted October 25, 2004.

* Reprint requests and correspondence: Dr. Jean-Jacques Goy, Chemin des Croix-Rouges 7, 1007 Lausanne, Switzerland (Email: jjgoy{at}goyman.com).

OBJECTIVES: We conducted this trial to assess whether a sirolimus-eluting stent (SES) produces similar results to a paclitaxel-eluting stent (PES) when used in the real world of interventional cardiology.

BACKGROUND: Several drug-eluting stents have been shown to exert a beneficial effect on restenosis when used in the treatment of coronary artery disease. Any potential superiority of one drug over the others, however, is still unknown.

METHODS: To evaluate whether a PES or an SES is superior in daily practice, we randomized all patients suitable to receive a drug-eluting stent in our institution. Clinical follow-up was obtained after at least six months.

RESULTS: A total of 202 patients were included in this trial. One hundred patients received a PES and 102 received an SES. Procedural success was 99% in both groups. Incidence of major adverse cardiac events at follow-up (mean 7 ± 2 months) was 4% with the PES and 6% with the SES (p = 0.8). The need for target lesion revascularization was very low in both groups (1% with the PES and 3% with the SES).

CONCLUSIONS: Our results confirm that the high success rate obtained with both stents in randomized trials can be replicated in routine clinical practice. In this small group of patients we were unable to show any advantage of one stent over the other.

Abbreviations and Acronyms
  MACE = major adverse cardiac events
  MI = myocardial infarction
  PCI = percutaneous coronary intervention
  PES = paclitaxel-eluting stent
  SES = sirolimus-eluting stent




This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
S.-W. Lee, S.-W. Park, Y.-H. Kim, S.-C. Yun, D.-W. Park, C. W. Lee, M.-K. Hong, K.-S. Rhee, J. K. Chae, J.-K. Ko, et al.
A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus
J. Am. Coll. Cardiol., August 26, 2008; 52(9): 727 - 733.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
E. Mahmud, G. Bromberg-Marin, V. Palakodeti, L. Ang, D. Creanga, and A. N. DeMaria
Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2385 - 2395.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
T. Cyrus, H. Zhang, J. S. Allen, T. A. Williams, G. Hu, S. D. Caruthers, S. A. Wickline, and G. M. Lanza
Intramural Delivery of Rapamycin With {alpha}v{beta}3-Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury
Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 820 - 826.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
G. Godet, Y. Le Manach, F. Lesache, S. Perbet, and P. Coriat
Drug-eluting stent thrombosis in patients undergoing non-cardiac surgery: is it always a problem?
Br. J. Anaesth., April 1, 2008; 100(4): 472 - 477.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
A. M. Galloe, L. Thuesen, H. Kelbaek, P. Thayssen, K. Rasmussen, P. R. Hansen, N. Bligaard, K. Saunamaki, A. Junker, J. Aaroe, et al.
Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice: The SORT OUT II Randomized Trial
JAMA, January 30, 2008; 299(4): 409 - 416.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. Mukherjee and D. J. Moliterno
Effectiveness of Drug-Eluting Stents in Real-World Patients
JAMA, January 30, 2008; 299(4): 454 - 455.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
American College of Cardiology/American Heart Asso, 2007 Writing Group to Review New Evidence and Upda, S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, and D. O. Williams
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
J. Am. Coll. Cardiol., January 15, 2008; 51(2): 172 - 209.
[Full Text] [PDF]

Home page
 CirculationHome page
S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, D. O. Williams, 2005 WRITING COMMITTEE MEMBERS, S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, et al.
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee
Circulation, January 15, 2008; 117(2): 261 - 295.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. Schomig, A. Dibra, S. Windecker, J. Mehilli, J. Suarez de Lezo, C. Kaiser, S.-J. Park, J.-J. Goy, J.-H. Lee, E. Di Lorenzo, et al.
A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1373 - 1380.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
C. A. Simonton, B. Brodie, B. Cheek, F. Krainin, C. Metzger, J. Hermiller, S. Juk, P. Duffy, A. Humphrey, M. Nussbaum, et al.
Comparative Clinical Outcomes of Paclitaxel- and Sirolimus-Eluting Stents: Results From a Large Prospective Multicenter Registry STENT Group
J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1214 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
C. Bode and M. Zehender
The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis
Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D10 - D19.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Daemen and P. W. Serruys
Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same?
Circulation, July 17, 2007; 116(3): 316 - 328.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Moreno, C. Fernandez, A. Sanchez-Recalde, G. Galeote, L. Calvo, F. Alfonso, R. Hernandez, R. Sanchez-Aquino, D. J. Angiolillo, S. Villarreal, et al.
Clinical impact of in-stent late loss after drug-eluting coronary stent implantation
Eur. Heart J., July 1, 2007; 28(13): 1583 - 1591.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. Cosgrave, G. Melzi, S. Corbett, G. G.L. Biondi-Zoccai, P. Agostoni, R. Babic, F. Airoldi, A. Chieffo, G. M. Sangiorgi, M. Montorfano, et al.
Comparable Clinical Outcomes With Paclitaxel- and Sirolimus-Eluting Stents in Unrestricted Contemporary Practice
J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2320 - 2328.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M. Maeng, L. Okkels Jensen, K. Rasmussen, J. Flensted Lassen, L. Romer Krusell, P. Thayssen, and L. Thuesen
Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent
Heart, June 1, 2007; 93(6): 694 - 697.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
N. Beohar, C. J. Davidson, K. E. Kip, L. Goodreau, H. A. Vlachos, S. N. Meyers, K. H. Benzuly, J. D. Flaherty, M. J. Ricciardi, C. L. Bennett, et al.
Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents
JAMA, May 9, 2007; 297(18): 1992 - 2000.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. E. Kandzari, M. B. Leon, J. J. Popma, P. J. Fitzgerald, C. O'Shaughnessy, M. W. Ball, M. Turco, R. J. Applegate, P. A. Gurbel, M. G. Midei, et al.
Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary Artery Disease: A Randomized Controlled Trial
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2440 - 2447.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
Y.-H. Kim, S.-W. Park, S.-W. Lee, D.-W. Park, S.-C. Yun, C. W. Lee, M.-K. Hong, H.-S. Kim, J.-K. Ko, J.-H. Park, et al.
Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease
Circulation, November 14, 2006; 114(20): 2148 - 2153.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Elezi, A. Dibra, U. Folkerts, J. Mehilli, S. Heigl, A. Schomig, and A. Kastrati
Cost Analysis From Two Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in High-Risk Patients With Coronary Artery Disease
J. Am. Coll. Cardiol., July 18, 2006; 48(2): 262 - 267.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. A. Nienaber
Guidelines for percutaneous coronary interventions
Eur. Heart J., July 2, 2006; 27(14): 1757 - 1757.
[Full Text] [PDF]

Home page
 CirculationHome page
C. Rogers and E. R. Edelman
Pushing Drug-Eluting Stents Into Uncharted Territory: Simpler Than You Think--More Complex Than You Imagine
Circulation, May 16, 2006; 113(19): 2262 - 2265.
[Full Text] [PDF]

Home page
 CirculationHome page
A. Kastrati, A. Dibra, J. Mehilli, S. Mayer, S. Pinieck, J. Pache, J. Dirschinger, and A. Schomig
Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents
Circulation, May 16, 2006; 113(19): 2293 - 2300.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1689 - 1706.
[Full Text] [PDF]

Home page
 JAMAHome page
D. R. Holmes Jr, P. Teirstein, L. Satler, M. Sketch, J. O'Malley, J. J. Popma, R. E. Kuntz, P. J. Fitzgerald, H. Wang, E. Caramanica, et al.
Sirolimus-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents: The SISR Randomized Trial
JAMA, March 15, 2006; 295(11): 1264 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. G. Raja
Drug-Eluting Stents and the Future of Coronary Artery Bypass Surgery: Facts and Fiction.
Ann. Thorac. Surg., March 1, 2006; 81(3): 1162 - 1171.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M.-C. Morice, A. Colombo, B. Meier, P. Serruys, C. Tamburino, G. Guagliumi, E. Sousa, H.-P. Stoll, and for the REALITY Trial Investigators
Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions: The REALITY Trial: A Randomized Controlled Trial
JAMA, February 22, 2006; 295(8): 895 - 904.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, D. Sahn, and S. Tsimikas
Highlights of the Year in JACC 2005
J. Am. Coll. Cardiol., January 3, 2006; 47(1): 184 - 202.
[Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. J. Nawarskas and L. A. Osborn
Paclitaxel-eluting stents in coronary artery disease
Am. J. Health Syst. Pharm., November 1, 2005; 62(21): 2241 - 2251.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. Windecker, A. Remondino, F. R. Eberli, P. Juni, L. Raber, P. Wenaweser, M. Togni, M. Billinger, D. Tuller, C. Seiler, et al.
Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization
N. Engl. J. Med., August 18, 2005; 353(7): 653 - 662.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. J. Moliterno
Healing Achilles -- Sirolimus versus Paclitaxel
N. Engl. J. Med., August 18, 2005; 353(7): 724 - 727.
[Full Text] [PDF]

Home page
 JAMAHome page
A. Kastrati, A. Dibra, S. Eberle, J. Mehilli, J. Suarez de Lezo, J.-J. Goy, K. Ulm, and A. Schomig
Sirolimus-Eluting Stents vs Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease: Meta-analysis of Randomized Trials
JAMA, August 17, 2005; 294(7): 819 - 825.
[Abstract] [Full Text] [PDF]


 
  cardiology careers collections past issues search home